This article by Dr Eleni Theocharidou et al. is published in Current Pharmaceutical Design, Volume 24, Issue 31, 2018 BENTHAM SCIENCE PUBLISHERS Statin treatment exhibits a beneficial effect in patients of cardiovascular diseases (CVD) and non–alcoholic fatty liver disease (NAFLD). Statins are common treatments for such conditions. The role of proprotein convertase subtilisin kexin type-9 (PCSK9) in the pathogenesis of NAFLD is summarized...
Tag: <span>fatty liver disease</span>
Post
New treatment for fatty liver disease and type 2 diabetes burns up fat in liver
A new treatment for nonalcoholic fatty liver disease and type 2 diabetes is being developed for clinical trial in Sweden. Researchers in Sweden are planning the clinical trial of a new treatment for nonalcoholic fatty liver disease and type 2 diabetes which harnesses liver cells’ own ability to burn accumulated fats. In a study involving...